Camillio Porta

List of Publications by Year in Descending Order

339 papers	25,610 citations	49 h-index	157 g-index
392 ext. papers	31,428 ext. citations	6.2 avg, IF	6.54 L-index

#	Paper	IF	Citations
339	Renal cell carcinoma and viral infections: A dangerous relationship?. *World Journal of Nephrology*, **2022**, 11, 1-12	3.6	0
338	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.. *Therapeutic Advances in Medical Oncology*, **2022**, 14, 17588359221079580	5.4	0
337	SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM).. *Radiologia Medica*, **2022**, 1	6.5	1
336	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations.. *Cancer Treatment Reviews*, **2022**, 105, 102379	14.4	1
335	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	5
334	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.. *Lancet Oncology, The*, **2022**,	21.7	6
333	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. *Journal of Personalized Medicine*, **2022**, 12, 727	3.6	0
332	Abemaciclib for malignant pleural mesothelioma. *Lancet Oncology, The*, **2022**, 23, e237	21.7	0
331	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. *European Urology*, **2021**, 81, 266-266	10.2	4
330	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. *Japanese Journal of Clinical Oncology*, **2021**, 51, 484-491	2.8	1
329	Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors. *American Journal of Translational Research (discontinued)*, **2021**, 13, 8598-8610	3	
328	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. *BMJ Open*, **2021**, 11, e049128	3	1
327	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. *World Journal of Clinical Oncology*, **2021**, 12, 1037-1046	2.5	
326	RAMES study: is there really a role for VEGF inhibition in mesothelioma?. *Lancet Oncology, The*, **2021**, 22, e532	21.7	2
325	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. *Therapeutic Advances in Urology*, **2021**, 13, 17562872211054302	3.2	1
324	Renal Cancer. *UNIPA Springer Series*, **2021**, 755-774	0.1	0
323	Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors. *Cancer Management and Research*, **2021**, 13, 7623-7636	3.6	0

322	Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. *Human Vaccines and Immunotherapeutics*, **2021**, 1-9	4.4	1
321	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. *Biologics: Targets and Therapy*, **2021**, 15, 441-450	4.4	0
320	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2021**, 384, 829-841	59.2	280
319	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. *Cancer Treatment Reviews*, **2021**, 94, 102157	14.4	1
318	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. *Current Opinion in Urology*, **2021**, 31, 236-241	2.8	0
317	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *New England Journal of Medicine*, **2021**, 384, 1289-1300	59.2	263
316	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. *Cancers*, **2021**, 13,	6.6	3
315	The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. *Genes*, **2021**, 12,	4.2	3
314	Impact of SARS-CoV-2 Pandemic on Kidney Cancer Management. *Kidney Cancer*, **2021**, 5, 93-106	0.6	
313	Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. *Cancers*, **2021**, 13,	6.6	7
312	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
311	Uterine carcinosarcoma: An overview. *Critical Reviews in Oncology/Hematology*, **2021**, 163, 103369	7	3
310	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. *European Urology*, **2021**, 79, 659-662	10.2	30
309	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. *Clinical Genitourinary Cancer*, **2021**, 19, e84-e91	3.3	11
308	Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art. *Journal of Bone Oncology*, **2021**, 26, 100337	4.5	0
307	Preventive strategies for acute kidney injury in cancer patients. *CKJ: Clinical Kidney Journal*, **2021**, 14, 70-83	4.5	9
306	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. *Cancer Immunology, Immunotherapy*, **2021**, 70, 1667-1678	7.4	8
305	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. *European Urology Oncology*, **2021**, 4, 274-281	6.7	5

304	Second-line treatment in renal cell carcinoma: clinical experience and decision making. *Therapeutic Advances in Urology*, **2021**, 13, 17562872211022870	3.2	1
303	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. *JAMA Network Open*, **2021**, 4, e2021869	10.4	23
302	TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.. *Journal of Clinical Oncology*, **2021**, 39, 278-278	2.2	0
301	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. *ESMO Open*, **2021**, 6, 100030	6	17
300	The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2021**, 39, 339-339	2.2	2
299	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. *Journal of Clinical Oncology*, **2021**, 39, 269-269	2.2	9
298	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. *Journal of Clinical Oncology*, **2021**, 39, 313-313	2.2	1
297	Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.. *Journal of Clinical Oncology*, **2021**, 39, 308-308	2.2	19
296	Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls. *Cancers*, **2021**, 13,	6.6	2
295	Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?. *Future Oncology*, **2021**, 17, 3579-3584	3.6	0
294	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. *European Journal of Cancer*, **2021**, 155, 56-63	7.5	3
293	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. *Translational Oncology*, **2021**, 14, 101153	4.9	0
292	The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. *Journal of Neuroendocrinology*, **2021**, 33, e13041	3.8	1
291	The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. *Microvascular Research*, **2021**, 138, 104189	3.7	3
290	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. *Cancer Treatment Reviews*, **2021**, 100, 102288	14.4	1
289	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211019642	5.4	11
288	A Glimpse in the Future of Malignant Mesothelioma Treatment.. *Frontiers in Pharmacology*, **2021**, 12, 809337	5.6	1
287	Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. *Metabolites*, **2020**, 10,	5.6	21

286	Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. *OncoImmunology*, **2020**, 9, 1846901	7.2	9
285	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. *Frontiers in Immunology*, **2020**, 11, 574271	8.4	24
284	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. *Journal of Clinical Pathology*, **2020**,	3.9	1
283	Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. *Tumori*, **2020**, 300891620915786	1.7	0
282	RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane. *Oncology Reviews*, **2020**, 14, 493	4.3	
281	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. *Clinical Genitourinary Cancer*, **2020**, 18, 477-488	3.3	8
280	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. *Clinical Genitourinary Cancer*, **2020**, 18, e588-e597	3.3	4
279	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. *Frontiers in Immunology*, **2020**, 11, 490	8.4	21
278	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. *Pathology*, **2020**, 52, 297-309	1.6	18
277	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *European Urology Oncology*, **2020**, 3, 530-539	6.7	14
276	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. *Cancer Treatment Reviews*, **2020**, 84, 101966	14.4	20
275	Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. *ESMO Open*, **2020**, 5,	6	6
274	Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors **2020**, 299-306.e1		
273	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2020**, 38, 5062-5062	2.2	1
272	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 5071-5071	2.2	2
271	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. *Journal of Clinical Oncology*, **2020**, 38, 609-609	2.2	32
270	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2020**, 38, 642-642	2.2	3
269	Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.. *Journal of Clinical Oncology*, **2020**, 38, 632-632	2.2	

268	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. *Journal of Clinical Oncology*, **2020**, 38, 5070-5070	2.2	
267	Vitamin K effects in human health: new insights beyond bone and cardiovascular health. *Journal of Nephrology*, **2020**, 33, 239-249	4.8	20
266	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. *European Urology*, **2020**, 77, 449-453	10.2	27
265	Conventional chemotherapy **2020**, 127-153.e11		1
264	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. *Lancet Oncology, The*, **2020**, 21, 95-104	21.7	70
263	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial **2020**, 8,		68
262	The basics of onco-nephrology in the renal clinic. *Journal of Nephrology*, **2020**, 33, 1143-1149	4.8	
261	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open*, **2020**, 5, e001079	6	109
260	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. *Cancers*, **2020**, 12,	6.6	6
259	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. *Kidney International*, **2020**, 98, 1407-1418	9.9	3
258	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. *OncoImmunology*, **2020**, 9, 1832348	7.2	27
257	Non-Melanoma Skin Cancers: Biological and Clinical Features. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	28
256	Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. *European Journal of Cancer*, **2020**, 136, 195-203	7.5	24
255	An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. *Journal of Medical Economics*, **2020**, 23, 1579-1587	2.4	2
254	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open*, **2020**, 5,	6	12
253	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and´managing kidney cancer. *Kidney International*, **2020**, 98, 1108-1119	9.9	10
252	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. *Frontiers in Oncology*, **2020**, 10, 581130	5.3	4
251	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 2199-2204	4	1

250	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 1574-1588	21.7	115
249	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. *European Urology*, **2020**, 78, 783-785	10.2	8
248	Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data. *Journal of Onco-Nephrology*, **2020**, 4, 153-164	0.2	
247	Large Extracellular Vesicles-A New Frontier of Liquid Biopsy in Oncology. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
246	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. *Expert Opinion on Drug Safety*, **2020**, 19, 1329-1338	4.1	34
245	Exploring the Spectrum of Kidney Ciliopathies. *Diagnostics*, **2020**, 10,	3.8	1
244	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. *European Urology*, **2019**, 76, 861-867	10.2	39
243	Metastatic renal cell carcinoma cells growing in 3D on poly-D-lysine or laminin present a stem-like phenotype and drug resistance. *Oncology Reports*, **2019**, 42, 1878-1892	3.5	5
242	Targeting angiogenesis in metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2019**, 19, 245-257	3.5	4
241	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. *Future Oncology*, **2019**, 15, 929-941	3.6	23
240	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. *Kidney International*, **2019**, 96, 555-567	9.9	25
239	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. *Critical Reviews in Oncology/Hematology*, **2019**,	7	7
238	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet, The*, **2019**, 393, 2404-2415	40	490
237	AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer. *BJU International*, **2019**, 124, 693	5.6	19
236	Immune-based combination therapy for metastatic kidney cancer. *Nature Reviews Nephrology*, **2019** , 15, 324-325	14.9	2
235	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). *Oncologist*, **2019**, 24, 491-497	5.7	17
234	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. *Nature Reviews Nephrology*, **2019**, 15, 423-433	14.9	34
233	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. *Immunotherapy*, **2019**, 11, 631-643	3.8	21

232	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program **2019**, 7, 99		71
231	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 529.e1-529.e7	2.8	4
230	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. *BJU International*, **2019**, 123, 98-105	5.6	48
229	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. *Critical Reviews in Oncology/Hematology*, **2019**, 139, 149-157	7	7
228	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 1370-1385	21.7	343
227	Toward a genome-based treatment landscape for renal cell carcinoma. *Critical Reviews in Oncology/Hematology*, **2019**, 142, 141-152	7	11
226	Renal cell carcinoma treatment after first-line combinations. *Lancet Oncology, The*, **2019**, 20, 1332-1334	21.7	5
225	Understanding the Mechanisms of Resistance in -Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	33
224	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. *Clinical Genitourinary Cancer*, **2019**, 17, e903-e908	3.3	16
223	Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma. *Cancer Genomics and Proteomics*, **2019**, 16, 299-307	3.3	6
222	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). *Tumori*, **2019**, 105, 3-12	1.7	7
221	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. *European Urology Oncology*, **2019**, 2, 603-604	6.7	1
220	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. *Nature Reviews Urology*, **2019**, 16, 655-673	5.5	12
219	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. *Critical Reviews in Oncology/Hematology*, **2019**, 144, 102812	7	5
218	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. *Journal of Clinical Oncology*, **2019**, 37, 4512-4512	2.2	21
217	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2019**, 37, 4572-4572	2.2	1
216	Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214.. *Journal of Clinical Oncology*, **2019**, 37, 4575-4575	2.2	3
215	Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. *Journal of Clinical Oncology*, **2019**, 37, 547-547	2.2	41

214	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. *Journal of Clinical Oncology*, **2019**, 37, 564-564	2.2	6
213	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. *Journal of Clinical Oncology*, **2019**, 37, 581-581	2.2	10
212	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. *Journal of Clinical Oncology*, **2019**, 37, e14054-e14054	2.2	
211	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. *Journal of Clinical Oncology*, **2019**, 37, e16109-e16109	2.2	
210	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. *Cancers*, **2019**, 12,	6.6	14
209	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, 425-435.e4	3.3	9
208	Acute Kidney Injury in Oncology and Tumor Lysis Syndrome **2019**, 234-250.e1		1
207	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. *Oncologist*, **2019**, 24, 338-348	5.7	21
206	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *European Urology Oncology*, **2019**, 2, 643-648	6.7	19
205	Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. *Hepatology*, **2019**, 69, 1165-1179	11.2	31
204	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. *Cytotechnology*, **2019**, 71, 149-163	2.2	13
203	Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison. *Critical Reviews in Oncology/Hematology*, **2019**, 139, 143-148	7	7
202	Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. *Journal of Nephrology*, **2019**, 32, 57-64	4.8	7
201	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. *Lancet Oncology, The*, **2018**, 19, 682-693	21.7	216
200	Acute Kidney Injury in Cancer Patients. *Contributions To Nephrology*, **2018**, 193, 137-148	1.6	14
199	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2018**, 378, 1277-1290	59.2	2064
198	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. *Pathology and Oncology Research*, **2018**, 24, 447-456	2.6	12
197	The role of tivozanib in advanced renal cell carcinoma therapy. *Expert Review of Anticancer Therapy*, **2018**, 18, 1113-1124	3.5	8

196	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2018**, 70, 112-117	14.4	11
195	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). *Kidney Cancer*, **2018**, 2, 31-36	0.6	6
194	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. *Anti-Cancer Drugs*, **2018**, 29, 705-709	2.4	1
193	Opening an onconephrology clinic: recommendations and basic requirements. *Nephrology Dialysis Transplantation*, **2018**, 33, 1503-1510	4.3	26
192	Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. *Global & Regional Health Technology Assessment*, **2018**, 2018, 2284240318790 73	0.2	
191	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. *Critical Reviews in Oncology/Hematology*, **2018**, 132, 89-99	7	22
190	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer*, **2018**, 124, 3677-3683	6.4	38
189	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. *Targeted Oncology*, **2018**, 13, 705-714	5	24
188	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. *Future Oncology*, **2018**, 14, 1347-1354	3.6	7
187	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. *Clinical Genitourinary Cancer*, **2018**, 16, 355-359.e1	3.3	22
186	Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). *Journal of Nephrology*, **2017**, 30, 171-180	4.8	23
185	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. *Applied Immunohistochemistry and Molecular Morphology*, **2017**, 25, 39-43	1.9	7
184	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 205-216	4	5
183	How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2017**, 17, 227-233	3.5	8
182	Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. *Clinical Therapeutics*, **2017**, 39, 567-580.e2	3.5	18
181	Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. *BJU International*, **2017**, 119, 846-853	5.6	3
180	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. *Expert Opinion on Biological Therapy*, **2017**, 17, 151-162	5.4	4
179	Adjuvant therapy in renal cell carcinoma. *Cancer Treatment Reviews*, **2017**, 60, 152-157	14.4	25

178	Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. *Oncotarget*, **2017**, 8, 7328-7335	3.3	16
177	Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. *Clinical Genitourinary Cancer*, **2017**,	3.3	10
176	CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. *British Journal of Cancer*, **2017**, 117, 947-953	8.7	14
175	Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. *Therapeutic Advances in Urology*, **2017**, 9, 195-207	3.2	27
174	Renin angiotensin system deregulation as renal cancer risk factor. *Oncology Letters*, **2017**, 14, 5059-5068	2.6	26
173	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. *Frontiers in Pharmacology*, **2017**, 8, 329	5.6	5
172	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. *Oncotarget*, **2017**, 8, 14408-14415	3.3	18
171	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. *World Journal of Gastroenterology*, **2017**, 23, 2448-2452	5.6	9
170	Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus **2017**, 273-294		1
169	Onco-nephrology: a decalogue. *Nephrology Dialysis Transplantation*, **2016**, 31, 515-9	4.3	41
168	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. *European Urology*, **2016**, 69, 345-51	10.2	42
167	Choosing the right cell line for renal cell cancer research. *Molecular Cancer*, **2016**, 15, 83	42.1	129
166	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. *Clinical Genitourinary Cancer*, **2016**, 14, 406-414	3.3	8
165	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. *Targeted Oncology*, **2016**, 11, 143-8	5	108
164	Transplantation of kidneys with tumors. *Journal of Nephrology*, **2016**, 29, 163-168	4.8	8
163	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2016**, 22, 2445-2452	12.9	150
162	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. *Critical Reviews in Oncology/Hematology*, **2016**, 98, 254-63	7	1
161	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. *Targeted Oncology*, **2016**, 11, 345-51	5	48

160	Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 643-55	4	9
159	Glomerular diseases and cancer: evaluation of underlying malignancy. *Journal of Nephrology*, **2016**, 29, 143-152	4.8	33
158	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. *Oncotarget*, **2016**, 7, 72622-72633	3.3	52
157	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. *Oncotarget*, **2016**, 7, 33381-90	3.3	10
156	Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy. *Current Medicinal Chemistry*, **2016**, 23, 3450-3480	4.3	44
155	Insulin-like growth factor-1 signaling in renal cell carcinoma. *BMC Cancer*, **2016**, 16, 453	4.8	30
154	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. *PLoS ONE*, **2016**, 11, e0151662	3.7	39
153	Endoplasmic Reticulum Ca(2+) Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells. *Journal of Cellular Biochemistry*, **2016**, 117, 2260-71	4.7	22
152	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. *Future Oncology*, **2016**, 12, 533-49	3.6	6
151	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. *Journal of Clinical Oncology*, **2016**, 34, 2429-30	2.2	3
150	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. *European Journal of Cancer*, **2016**, 69, 226-235	7.5	45
149	Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. *Future Oncology*, **2015**, 11, 39-50	3.6	44
148	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. *Journal of Experimental and Clinical Cancer Research*, **2015**, 34, 10	12.8	50
147	Renal effects of targeted anticancer therapies. *Nature Reviews Nephrology*, **2015**, 11, 354-70	14.9	74
146	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. *Annals of Surgical Oncology*, **2015**, 22, 2094-100	3.1	48
145	Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. *Clinical Genitourinary Cancer*, **2015**, 13, 287-294	3.3	29
144	Renal cancer in kidney transplanted patients. *Journal of Nephrology*, **2015**, 28, 659-68	4.8	24
143	Tivantinib (ARQ197) in hepatocellular carcinoma. *Expert Review of Anticancer Therapy*, **2015**, 15, 615-22	3.5	13

142	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. *Targeted Oncology*, **2015**, 10, 517-22	5	32
141	Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. *Oncology*, **2015**, 88, 273-80	3.6	23
140	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. *Oncologist*, **2015**, 20, 1028-35	5.7	22
139	Renal toxicity of anticancer agents targeting HER2 and EGFR. *Journal of Nephrology*, **2015**, 28, 647-57	4.8	28
138	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. *Critical Reviews in Oncology/Hematology*, **2015**, 93, 50-9	7	11
137	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. *Journal of Urology*, **2015**, 193, 41-7	2.5	43
136	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. *European Urology*, **2015**, 67, 100-110	10.2	106
135	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project *Annals of Oncology*, **2015**, 26, 2392-8	10.3	22
134	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. *Future Oncology*, **2015**, 11, 3159-66	3.6	9
133	The role of the cell-cell interactions in cancer progression. *Journal of Cellular and Molecular Medicine*, **2015**, 19, 283-96	5.6	60
132	Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers. *Tumori*, **2015**, 101, 139-43	1.7	5
131	Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?. *Journal of Clinical Oncology*, **2015**, 33, 3219-20	2.2	3
130	Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. *Liver International*, **2015**, 35, 2001-8	7.9	37
129	The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. *PLoS ONE*, **2015**, 10, e0120427	3.7	8
128	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. *Current Drug Targets*, **2015**, 16, 164-70	3	36
127	Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies **2015**, 555-575		
126	Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. *Journal of Clinical Oncology*, **2014**, 32, 1412-8	2.2	314
125	Considerations for the design of future clinical trials in metastatic renal cell carcinoma. *Clinical Genitourinary Cancer*, **2014**, 12, 1-12	3.3	6

124	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 286-96	21.7	215
123	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. *International Journal of Oncology*, **2014**, 44, 5-16	4.4	30
122	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. *Hepatic Oncology*, **2014**, 1, 181-188	4	14
121	Predicting efficacy of sunitinib in metastatic renal cell carcinoma. *Current Biomarker Findings*, **2014**, 43		
120	Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R□nd NKG2D triggering. *Cancer Research*, **2014**, 74, 68-80	10.1	33
119	Store-operated Ca2+ entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma. *BioMed Research International*, **2014**, 2014, 739494	3	41
118	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. *Future Oncology*, **2014**, 10, 1741-50	3.6	11
117	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. *Cancer Medicine*, **2014**, 3, 1517-26	4.8	41
116	Adjuvant low-dose interleukin-2 (IL-2) plus interferon-□(IFN-□in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). *Journal of Immunotherapy*, **2014**, 37, 440-7	5	46
115	Reply to S. Barni et Al and M. Sun et Al. *Journal of Clinical Oncology*, **2014**, 32, 3783-4	2.2	0
114	Targeting PI3K/Akt/mTOR Signaling in Cancer. *Frontiers in Oncology*, **2014**, 4, 64	5.3	773
113	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. *Clinical Genitourinary Cancer*, **2014**, 12, 262-9	3.3	8
112	Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. *Clinical Genitourinary Cancer*, **2013**, 11, 471-6	3.3	19
111	Evidence and experience for the management of metastatic renal cell carcinoma. *European Journal of Cancer, Supplement*, **2013**, 11, 1-8	1.6	2
110	Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). *European Urology*, **2013**, 63, 254-61	10.2	24
109	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. *Lancet Oncology, The*, **2013**, 14, 55-63	21.7	453
108	Axitinib dose titration: what's the limiting factor?. *Lancet Oncology, The*, **2013**, 14, 1152-4	21.7	6
107	Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. *Future Oncology*, **2013**, 9, 831-43	3.6	5

106	Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. *Oncology*, **2013**, 84, 115-22	3.6	70
105	Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes. *Tumori*, **2013**, 99, e282-e284	1.7	1
104	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. *PLoS ONE*, **2013**, 8, e83026	3.7	52
103	Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. *Anticancer Research*, **2013**, 33, 3487-94	2.3	50
102	A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. *Anticancer Research*, **2013**, 33, 4999-5004	2.3	3
101	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. *Critical Reviews in Oncology/Hematology*, **2012**, 82, 323-37	7	29
100	Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. *European Urology*, **2012**, 61, 826-33	10.2	51
99	Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braud Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. Eur Urol 2012;61:826–33. *European Urology*, **2012**, 62, e7-e8	10.2	
98	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. *BJU International*, **2012**, 110, 692-8	5.6	37
97	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *Journal of Hepatology*, **2012**, 57, 821-9	13.4	589
96	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. *Cancer Treatment Reviews*, **2012**, 38, 127-32	14.4	6
95	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. *European Journal of Cancer*, **2012**, 48, 2983-92	7.5	25
94	mRCC management: past, present and future. *European Journal of Cancer, Supplement*, **2012**, 10, 1-11	1.6	
93	Treatment selection in metastatic renal cell carcinoma: expert consensus. *Nature Reviews Clinical Oncology*, **2012**, 9, 327-37	19.4	108
92	Sequential therapy in metastatic renal cell carcinoma: what comes next?. *Medical Oncology*, **2012**, 29, 1914-5	3.7	1
91	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. *Expert Review of Anticancer Therapy*, **2012**, 12, 1571-7	3.5	31
90	Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. *PLoS ONE*, **2012**, 7, e42541	3.7	112
89	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2012**, 12, 1089-96	3.5	5

88	A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. *Oncology*, **2012**, 82, 333-40	3.6	28
87	Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. *Future Oncology*, **2012**, 8, 1605-12	3.6	7
86	The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. *Future Oncology*, **2012**, 8, 1051-7	3.6	10
85	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)PISCES study, NCT 01064310.. *Journal of Clinical Oncology*, **2012**, 30, CRA4502-CRA4502	2.2	26
84	Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial. *Translational Andrology and Urology*, **2012**, 1, 120-2	2.3	1
83	Bevacizumab plus interferon- versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. *Clinical Drug Investigation*, **2011**, 31, 507-17	3.2	10
82	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. *European Journal of Cancer*, **2011**, 47, 1287-98	7.5	118
81	Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. *The Journal of Supportive Oncology*, **2011**, 9, 13-23		33
80	Indirect treatment comparison of bevacizumab + interferon-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. *ClinicoEconomics and Outcomes Research*, **2011**, 3, 19-27	1.7	5
79	Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?. *Journal of Cancer*, **2011**, 2, 333-8	4.5	37
78	Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. *PLoS ONE*, **2011**, 6, e19234	3.7	136
77	Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction. *Urologia*, **2011**, 78 Suppl 18, 9-15	1.2	
76	A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. *BJU International*, **2011**, 107, 1190-9	5.6	17
75	Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. *BJU International*, **2011**, 107, 747-748	5.6	3
74	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. *BJU International*, **2011**, 108, E250-7	5.6	67
73	Toxicities of targeted therapy and their management in kidney cancer. *European Urology*, **2011**, 59, 526-40	10.2	89
72	Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. *BMC Cancer*, **2011**, 11, 105	4.8	28
71	Expression pattern of receptor activator of NFB (RANK) in a series of primary solid tumors and related bone metastases. *Journal of Cellular Physiology*, **2011**, 226, 780-4	7	95

70	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. *Cancer*, **2011**, 117, 501-9	6.4	110
69	Optimizing treatment for metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2011**, 11, 1901-11	3.5	4
68	Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. *Immunotherapy*, **2011**, 3, 487-90	3.8	2
67	Combination therapy & future directions in RCC **2011**, 126-142		
66	Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. *Kidney International*, **2010**, 77, 809-15	9.9	78
65	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. *Cancer Treatment Reviews*, **2010**, 36, 16-23	14.4	42
64	Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. *European Journal of Cancer*, **2010**, 46, 2432-40	7.5	62
63	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. *Cancer Immunology, Immunotherapy*, **2010**, 59, 553-61	7.4	19
62	Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. *Cancer*, **2010**, 116, 4256-65	6.4	904
61	Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. *World Journal of Hepatology*, **2010**, 2, 103-13	3.4	13
60	Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. *Journal of Urology*, **2009**, 182, 2569-77	2.5	71
59	Tolerability of first-line therapy for metastatic renal cell carcinoma. *Cancer Treatment Reviews*, **2009**, 35, 297-307	14.4	36
58	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. *Lancet Oncology, The*, **2009**, 10, 757-63	21.7	478
57	Sorafenib tosylate in advanced kidney cancer: past, present and future. *Anti-Cancer Drugs*, **2009**, 20, 409-15	2.4	18
56	Use of Sorafenib in Two Metastatic Renal Cell Cancer Patients with End-Stage Renal Impairment Undergoing Replacement Hemodialysis. *Tumori*, **2009**, 95, 542-544	1.7	15
55	Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. *Tumori*, **2009**, 95, 542-4	1.7	3
54	Re: damien pouessel, stÞhane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81. *European Urology*, **2008**, 53, 1092-3	10.2	9
53	Sorafenib in advanced hepatocellular carcinoma. *New England Journal of Medicine*, **2008**, 359, 378-90	59.2	9089

52	Prognostic factors in advanced renal cell cancer. *European Journal of Cancer, Supplement*, **2008**, 6, 35-37	1.6	1
51	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet, The*, **2008**, 372, 449-56	40	2451
50	Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. *Clinical Cancer Research*, **2008**, 14, 541-8	12.9	59
49	Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. *Biologics: Targets and Therapy*, **2008**, 2, 601-9	4.4	30
48	Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. *Oncology Reports*, **2008**, 20, 1511-9	3.5	2
47	Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. *Scientific World Journal, The*, **2007**, 7, 837-49	2.2	21
46	Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. *Cancer Chemotherapy and Pharmacology*, **2007**, 59, 149-50	3.5	55
45	Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. *Clinical Cancer Research*, **2007**, 13, 5942-51	12.9	81
44	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. *Thorax*, **2007**, 62, 690-5	7.3	40
43	Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. *Anticancer Research*, **2007**, 27, 165-73	2.3	25
42	Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study. *Cancer*, **2006**, 107, 2898-905	6.4	39
41	Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer. *Expert Review of Anticancer Therapy*, **2006**, 6, 141-52	3.5	4
40	Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma. *Cancer Treatment Reviews*, **2006**, 32, 229-33	14.4	5
39	Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. *Lung Cancer*, **2005**, 48, 429-34	5.9	47
38	New agents in the management of advanced mesothelioma. *Seminars in Oncology*, **2005**, 32, 336-50	5.5	35
37	SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. *Cancer Research*, **2005**, 65, 5256-62	10.1	74
36	Autoimmunity in thrombotic thrombocytopenic purpura. *Seminars in Thrombosis and Hemostasis*, **2005**, 31, 633-40	5.3	8
35	New Target Therapies for Malignant Mesothelioma **2005**, 765-777		

34	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. *Oncology Reports*, **2005**, 13, 689-95	3.5	5
33	Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. *Oncology Reports*, **2005**, 14, 113-20	3.5	18
32	Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2004**, 27, 155-63	2.7	14
31	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. *Oncology Reports*, **2004**, 12, 855-9	3.5	2
30	Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. *Cancer Immunology, Immunotherapy*, **2003**, 52, 359-66	7.4	29
29	Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. *International Journal of Molecular Medicine*, **2003**, 11, 161-7	4.4	4
28	Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2002**, 774, 17-24	3.2	41
27	The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. *American Journal of Respiratory Cell and Molecular Biology*, **2002**, 26, 189-93	5.7	62
26	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?. *Lung Cancer*, **2002**, 38, 159-62	5.9	6
25	Weekly taxanes in metastatic breast cancer (review). *Oncology Reports*, **2002**, 9, 1047-52	3.5	13
24	Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study. *Oncology Reports*, **2002**, 9, 1107-13	3.5	6
23	Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. *Cancer Chemotherapy and Pharmacology*, **2001**, 47, 423-8	3.5	10
22	Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. *Journal of Cellular Physiology*, **2000**, 185, 126-34	7	13
21	In vitro antioxidant properties of amifostine (WR-2721, Ethyol). *Cancer Chemotherapy and Pharmacology*, **2000**, 45, 172-6	3.5	54
20	'TUNEL' evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine. *British Journal of Haematology*, **1999**, 104, 424-5	4.5	6
19	Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. *Mayo Clinic Proceedings*, **1999**, 74, 570-4	6.4	18
18	Possible efficacy of allopurinol vaginal washings in the treatment of chemotherapy-induced vaginitis. *Cancer Chemotherapy and Pharmacology*, **1998**, 41, 171-2	3.5	2
17	Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer. *British Journal of Haematology*, **1998**, 100, 607-9	4.5	9

16	Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin 2 immunotherapy. *Journal of the National Cancer Institute*, **1997**, 89, 1545	9.7	5
15	Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. *Leukemia and Lymphoma*, **1996**, 23, 267-75	1.9	20
14	Nitrite and Nitrate Plasma Levels, as Markers for Nitric Oxide Synthesis, in Thrombotic Thrombocytopenic Purpura (TTP). *Hematology*, **1996**, 1, 239-46	2.2	3
13	Thrombotic thrombocytopenic purpura and relapses: why do case series differ? The Italian Cooperative Group for TTP. *American Journal of Hematology*, **1996**, 52, 215-6	7.1	2
12	5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. *Oncology*, **1995**, 52, 487-91	3.6	46
11	HLA-A, B, C, DR and DQ expression and hepatocellular carcinoma: study of 205 Italian subjects. *Cancer Letters*, **1995**, 98, 121-125	9.9	4
10	Utility of embolization of chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. *Cancer*, **1995**, 75, 2782-4	6.4	3
9	Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth. *International Journal of Cancer*, **1995**, 62, 291-6	7.5	5
8	Nephrectomy as a component of systemic treatment for renal cell carcinoma patients. *Journal of Surgical Oncology*, **1994**, 56, 81-2	2.8	
7	Allopurinol mouthwashes in methotrexate-induced stomatitis. *Arthritis and Rheumatism*, **1994**, 37, 777-8		12
6	High-dose human immunoglobulins in thrombotic thrombocytopenic purpura. *American Journal of Hematology*, **1994**, 45, 99-100	7.1	3
5	Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1994**, 17, 246-7	2.7	34
4	Anti-HCV antibodies and hepatocellular carcinoma. Relationship in a medium-risk population. *Upsala Journal of Medical Sciences*, **1992**, 97, 261-6	2.8	4
3	Thrombotic thrombocytopenic purpura (TTP): Retrospective study of 84 patients and therapeutic prospects. *Transfusion Science*, **1992**, 13, 39-44		11
2	Autoantibody profile in thrombotic thrombocytopenic purpura. *Transfusion Science*, **1992**, 13, 33-36		2
1	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The Retry study from the Italian Group of Onco-Nephrology (G.I.O.N.). *Journal of Onco-Nephrology*,239936932210936	9.2	